DocWire News Editors

DocwireNews

Researchers assessed the implementation of specialized financial accounting and pharmacy technician personnel to provide assistance to patients receiving high-cost cancer chemotherapy and found that this was a benefit for patients, reduced the financial toxicity, and had a “positive budgetary impact,” according to the researchers.
The 340B drug pricing program was <a href="https://www.proxsysrx.com/a-comprehensive-guide-to-the-340b-drug-pricing-program/">created by Congress in 1992 to provide certain health care providers</a> significant discounts on prescription drugs. It allows eligible hospitals, clinics, pharmacies, nursing homes, home healthcare agencies, hospices, dialysis centers and long-term acute care facilities (among others) to replenish prescription inventories at prices far below market rates.
The results of the study were presented by Andrea Ledford, PharmD, MBA, BCOP, BCSCP, oncology pharmacy manager at the Orlando Health University of Florida Health Cancer Center, at HOPA’s 16th Annual Conference.
Between October 2015 and September 2016, researchers assessed a baseline cohort who were offered drug replacement only at the primary cancer center location. The copay program was initiated in October 2016 through October 2018 and expanded the number of onsite personnel, as well as expanded the program to three regional sites.
Patient financial benefit was assessed annually using actual drug cost or copy offset provided by the drug manufacturer. This only applied to injectable products administered in the infusion setting. The centralized copay assistance personnel collaborated with onsite personnel during the regional expansion, and hospital drug charges were reversed as patient benefit was received at each location.
The baseline primary center location realized $3,037,733 in drug replacement benefit with no regional site or copay benefit. During each year following implementation, the following drug replacement benefits costs were realized at the primary location:
<ul>
<li>2016: $3,465,754</li>
<li>2017: $4,310,177</li>
<li>2018: $4,233,990</li>
</ul>
The following copay assistance costs were:
<ul>
<li>2016: $349,933</li>
<li>2017: $755,369</li>
<li>2018: $807,171</li>
</ul>
In 2018, the three regional locations yielded $731,871, $897,986, and $707,426 in replacement benefit. The 2018 patient benefit divided by the total drug replacement expense yielded a financial ratio of 8.1% at the primary site and 7.7%, 6.5%, and 7.2% at the regional sites. The financial ratio of copay savings was 1.2%.
The additional personnel increased total patient benefit from $3,037,733 to $7,428,445 (P&lt;0.0001) and copay benefit from $0 to $807,171 (P&lt;0.0001).
“The payer mix and prescribing trends remained stable during this evaluation,” the authors noted. “The creation of a financial ratio for patient benefit compared [with] total actual pharmacy expense can be developed to assess program success using a range specific for each location.”
Reference
Ledford A, Laurazon R, Tavella-Bunca P, et al. Expansion of a pharmacy patient assistance program. Presented at HOPA 16th Annual Conference. March 11-14, 2020, Tampa, Florida.

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Rob Dillard

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

Pharmacy Patient Assistance Program Reduces Financial Toxicity

2020 HOPA Annual Conference

Researchers assessed the implementation of specialized financial accounting and pharmacy technician personnel to provide assistance to patients receiving high-cost cancer ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe